Alaunos Therapeutics Inc (STU:WEK)
€ 1.66 0 (-4.82%) Market Cap: 338.23 Mil Enterprise Value: 276.94 Mil PE Ratio: 0 PB Ratio: 0.84 GF Score: 55/100

ZIOPHARM Oncology Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 06:40PM GMT
Release Date Price: €2.14 (-1.83%)
David Novak
Raymond James - Analyst

Okay. I think we'll get started here. Welcome, everyone, to the Raymond James annual healthcare conference. I'm David Novak, senior biotech analyst here at RJ. And today, I have the pleasure of introducing ZIOPHARM, a clinical-stage biotech company utilizing non-viral gene transfer and conditionally activated cytokines to develop novel CAR-T and TCR therapies.

Joining me from the Company today for our informal fireside chat is Heidi Hagen, Interim CEO; and Dr. Raffaele Baffa, CMO. Thank you both very much for taking the time to chat with us today.

Heidi Hagen
ZIOPHARM Oncology, Inc. - Interim CEO

Well, thank you, David.

Raffaele Baffa
ZIOPHARM Oncology, Inc. - Chief Medical Officer

Thank you.

Questions & Answers

David Novak
Raymond James - Analyst

So, Heidi, perhaps a good place to kick us off today would be a bit of a discussion around some of the history of the Company, to the extent that you can speak to it.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot